Cargando…
Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589428/ https://www.ncbi.nlm.nih.gov/pubmed/32632928 http://dx.doi.org/10.1002/mp.14375 |
_version_ | 1783600576838238208 |
---|---|
author | Mora‐Ramirez, Erick Santoro, Lore Cassol, Emmanuelle Ocampo‐Ramos, Juan C. Clayton, Naomi Kayal, Gunjan Chouaf, Soufiane Trauchessec, Dorian Pouget, Jean‐Pierre Kotzki, Pierre‐Olivier Deshayes, Emmanuel Bardiès, Manuel |
author_facet | Mora‐Ramirez, Erick Santoro, Lore Cassol, Emmanuelle Ocampo‐Ramos, Juan C. Clayton, Naomi Kayal, Gunjan Chouaf, Soufiane Trauchessec, Dorian Pouget, Jean‐Pierre Kotzki, Pierre‐Olivier Deshayes, Emmanuel Bardiès, Manuel |
author_sort | Mora‐Ramirez, Erick |
collection | PubMed |
description | PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was performed on two patients during two cycles of PRRT with (177)Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit(®) (DTK) from Xeleris™ and HybridRecon‐Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time‐integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations. RESULTS: The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms. CONCLUSIONS: When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms. |
format | Online Article Text |
id | pubmed-7589428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75894282020-10-30 Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy Mora‐Ramirez, Erick Santoro, Lore Cassol, Emmanuelle Ocampo‐Ramos, Juan C. Clayton, Naomi Kayal, Gunjan Chouaf, Soufiane Trauchessec, Dorian Pouget, Jean‐Pierre Kotzki, Pierre‐Olivier Deshayes, Emmanuel Bardiès, Manuel Med Phys COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was performed on two patients during two cycles of PRRT with (177)Lu. Single photon emission computed tomography/computed tomography images were acquired at 4, 24, 72, and 192 h post injection. Reconstructed images were generated using Dosimetry Toolkit(®) (DTK) from Xeleris™ and HybridRecon‐Oncology version_1.3_Dicom (HROD) from HERMES. Reconstructed images using DTK were analyzed using the same software to calculate time‐integrated activity coefficients (TIAC), and mean absorbed doses were estimated using OLINDA/EXM V1.0 with mass correction. Reconstructed images from HROD were uploaded into PLANET® OncoDose from DOSIsoft, STRATOS from Phillips, Hybrid Dosimetry Module™ from HERMES, and SurePlan™ MRT from MIM. Organ masses, TIACs, and mean absorbed doses were calculated from each application using their recommendations. RESULTS: The majority of organ mass estimates varied by <9.5% between all platforms. The highest variability for TIAC results between platforms was seen for the kidneys (28.2%) for the two patients and the two treatment cycles. Relative standard deviations in mean absorbed doses were slightly higher compared with those observed for TIAC, but remained of the same order of magnitude between all platforms. CONCLUSIONS: When applying a similar processing approach, results obtained were of the same order of magnitude regardless of the platforms used. However, the comparison of the performances of currently available platforms is still difficult as they do not all address the same parts of the dosimetric analysis workflow. In addition, the way in which data are handled in each part of the chain from data acquisition to absorbed doses may be different, which complicates the comparison exercise. Therefore, the dissemination of commercial solutions for absorbed dose calculation calls for the development of tools and standards allowing for the comparison of the performances between dosimetric software platforms. John Wiley and Sons Inc. 2020-07-31 2020-09 /pmc/articles/PMC7589428/ /pubmed/32632928 http://dx.doi.org/10.1002/mp.14375 Text en © 2020 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY Mora‐Ramirez, Erick Santoro, Lore Cassol, Emmanuelle Ocampo‐Ramos, Juan C. Clayton, Naomi Kayal, Gunjan Chouaf, Soufiane Trauchessec, Dorian Pouget, Jean‐Pierre Kotzki, Pierre‐Olivier Deshayes, Emmanuel Bardiès, Manuel Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title | Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title_full | Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title_fullStr | Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title_full_unstemmed | Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title_short | Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy |
title_sort | comparison of commercial dosimetric software platforms in patients treated with (177)lu‐dotatate for peptide receptor radionuclide therapy |
topic | COMPUTATIONAL AND EXPERIMENTAL DOSIMETRY |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589428/ https://www.ncbi.nlm.nih.gov/pubmed/32632928 http://dx.doi.org/10.1002/mp.14375 |
work_keys_str_mv | AT moraramirezerick comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT santorolore comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT cassolemmanuelle comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT ocamporamosjuanc comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT claytonnaomi comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT kayalgunjan comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT chouafsoufiane comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT trauchessecdorian comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT pougetjeanpierre comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT kotzkipierreolivier comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT deshayesemmanuel comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy AT bardiesmanuel comparisonofcommercialdosimetricsoftwareplatformsinpatientstreatedwith177ludotatateforpeptidereceptorradionuclidetherapy |